遗传性血管性水肿治疗药物的临床研究进展  

Advances in the clinical research of drugs for the treatment of hereditary angioedema

作　　者：张凌凡 赵宇晗 李智慧 陈燕 郑岩 倪娜 ZHANG Ling-fan;ZHAO Yu-han;LI Zhi-hui;CHEN Yan;ZHENG Yan;NI Na(Clinical Research Center,China State Institute of Pharmaceutical Industry,Shanghai 200437,China;Shanghai Clinical Research Organization for Medicines,Shanghai 200437,China)

机构地区：[1]中国医药工业研究总院药物临床研究中心,上海200437 [2]上海瀛科隆医药开发有限公司,上海200437

出　　处：《世界临床药物》2020年第4期319-322,共4页World Clinical Drug

摘　　要：遗传性血管性水肿(hereditary angioedema,HAE)是一种罕见遗传病,其发病率低、治疗费用高,且目前国内并无有效治疗手段,严重影响患者的生活质量。本文主要综述艾替班特(icatibant)、艾卡拉肽(ecallantide)及重组人C1酯酶抑制剂(recombinant human C1 esterase inhibitor,rhC1INH)3种药物用于治疗HAE的临床研究进展,以期为临床治疗提供新的依据。Hereditary angioedema(HAE)is a rare genetic disease with low incidence and high treatment costs.Currently there is no effective treatment in China,and seriously affects patients’quality of life.This article reviewed the advances in clinical research of three drugs such as icatibant,ecallantide,and recombinant human C1 esterase inhibitor for treatment of HAE,in order to provide a new basis for clinical treatment.

关 键 词：遗传性血管性水肿 艾替班特 艾卡拉肽 重组人C1酯酶抑制剂 

分 类 号：R969.4[医药卫生—药理学]